Amoasii, L., Long, C., Li, H., Mireault, A.A., Shelton, J.M., SanchezOrtiz, E., McAnally, J.R., Bhattacharyya, S., Schmidt, F., Grimm, D.,
et al. (2017). Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy. Sci. Transl.
Med. 9, eaan8081.
Aoki, Y., Yokota, T., Nagata, T., Nakamura, A., Tanihata, J., Saito, T.,
Duguez, S.M.R., Nagaraju, K., Hoffman, E.P., Partridge, T., and
Takeda, S. (2012). Bodywide skipping of exons 45-55 in dystrophic
mdx52 mice by systemic antisense delivery. Proc. Natl. Acad. Sci.
USA 109, 13763–13768.
Bladen, C.L., Salgado, D., Monges, S., Foncuberta, M.E., Kekou, K.,
Kosma, K., Dawkins, H., Lamont, L., Roy, A.J., Chamova, T., et al.
(2015). The TREAT-NMD DMD Global Database: analysis of more
than 7,000 Duchenne muscular dystrophy mutations. Hum. Mutat. 36, 395–402.
Be´roud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V., Monnier, N., Moizard, M.P., Voelckel, M.A., Calemard, L.M., Boisseau, P., et al. (2007). Multiexon skipping leading
to an artificial DMD protein lacking amino acids from exons 45
through 55 could rescue up to 63% of patients with Duchenne
muscular dystrophy. Hum. Mutat. 28, 196–202.
Cameron, P., Coons, M.M., Klompe, S.E., Lied, A.M., Smith, S.C.,
Vidal, B., Donohoue, P.D., Rotstein, T., Kohrs, B.W., Nyer, D.B.,
et al. (2019). Harnessing type I CRISPR-Cas systems for genome engineering in human cells. Nat. Biotechnol. 37, 1471–1477.
Canver, M.C., Bauer, D.E., Dass, A., Yien, Y.Y., Chung, J., Masuda,
T., Maeda, T., Paw, B.H., and Orkin, S.H. (2014). Characterization
1764 Stem Cell Reports j Vol. 18 j 1753–1765 j September 12, 2023
of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J. Biol. Chem. 289, 21312–21324.
Choi, J., Chen, W., Suiter, C.C., Lee, C., Chardon, F.M., Yang, W.,
Leith, A., Daza, R.M., Martin, B., and Shendure, J. (2022). Precise
genomic deletions using paired prime editing. Nat. Biotechnol.
40, 218–226.
Dolan, A.E., Hou, Z., Xiao, Y., Gramelspacher, M.J., Heo, J., Howden, S.E., Freddolino, P.L., Ke, A., and Zhang, Y. (2019). Introducing a Spectrum of Long-Range Genomic Deletions in Human
Embryonic Stem Cells Using Type I CRISPR-Cas. Mol. Cell 74,
936–950.e5.
Doudna, J.A. (2020). The promise and challenge of therapeutic
genome editing. Nature 578, 229–236.
Echigoya, Y., Lim, K.R.Q., Nakamura, A., and Yokota, T. (2018).
Multiple Exon Skipping in the Duchenne Muscular Dystrophy
Hot Spots: Prospects and Challenges. J. Pers. Med. 8, 41.
El Refaey, M., Xu, L., Gao, Y., Canan, B.D., Adesanya, T.M.A.,
Warner, S.C., Akagi, K., Symer, D.E., Mohler, P.J., Ma, J., et al.
(2017). In Vivo Genome Editing Restores Dystrophin Expression
and Cardiac Function in Dystrophic Mice. Circ. Res. 121, 923–929.
Fairclough, R.J., Wood, M.J., and Davies, K.E. (2013). Therapy for
Duchenne muscular dystrophy: renewed optimism from genetic
approaches. Nat. Rev. Genet. 14, 373–378.
˜iz, G.M.N., Francipane, L., Marzese,
Ferreiro, V., Giliberto, F., Mun
D.M., Mampel, A., Roque´, M., Frechtel, G.D., and Szijan, I.
(2009). Asymptomatic Becker muscular dystrophy in a family
with a multiexon deletion. Muscle Nerve 39, 239–243.
Gee, P., Lung, M.S.Y., Okuzaki, Y., Sasakawa, N., Iguchi, T., Makita,
Y., Hozumi, H., Miura, Y., Yang, L.F., Iwasaki, M., et al. (2020).
Extracellular nanovesicles for packaging of CRISPR-Cas9 protein
and sgRNA to induce therapeutic exon skipping. Nat. Commun.
11, 1334.
Jiang, T., Zhang, X.O., Weng, Z., and Xue, W. (2022). Deletion and
replacement of long genomic sequences using prime editing. Nat.
Biotechnol. 40, 227–234.
Kagita, A., Lung, M.S.Y., Xu, H., Kita, Y., Sasakawa, N., Iguchi, T.,
Ono, M., Wang, X.H., Gee, P., and Hotta, A. (2021). Efficient
ssODN-Mediated Targeting by Avoiding Cellular Inhibitory RNAs
through Precomplexed CRISPR-Cas9/sgRNA Ribonucleoprotein.
Stem Cell Rep. 16, 985–996.
Kenjo, E., Hozumi, H., Makita, Y., Iwabuchi, K.A., Fujimoto, N.,
Matsumoto, S., Kimura, M., Amano, Y., Ifuku, M., Naoe, Y., et al.
(2021). Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice. Nat.
Commun. 12, 7101.
Koenig, M., Monaco, A.P., and Kunkel, L.M. (1988). The complete
sequence of dystrophin predicts a rod-shaped cytoskeletal protein.
Cell 53, 219–228.
Koo, T., Lu-Nguyen, N.B., Malerba, A., Kim, E., Kim, D., Cappellari,
O., Cho, H.Y., Dickson, G., Popplewell, L., and Kim, J.S. (2018).
Functional Rescue of Dystrophin Deficiency in Mice Caused by
Frameshift Mutations Using Campylobacter jejuni Cas9. Mol.
Ther. 26, 1529–1538.
Kudoh, H., Ikeda, H., Kakitani, M., Ueda, A., Hayasaka, M., Tomizuka, K., and Hanaoka, K. (2005). A new model mouse for
Duchenne muscular dystrophy produced by 2.4 Mb deletion of
dystrophin gene using Cre-loxP recombination system. Biochem.
Biophys. Res. Commun. 328, 507–516.
Nelson, C.E., Hakim, C.H., Ousterout, D.G., Thakore, P.I., Moreb,
E.A., Castellanos Rivera, R.M., Madhavan, S., Pan, X., Ran, F.A.,
Yan, W.X., et al. (2016). In vivo genome editing improves muscle
function in a mouse model of Duchenne muscular dystrophy. Science 351, 403–407.
Li, H.L., Fujimoto, N., Sasakawa, N., Shirai, S., Ohkame, T., Sakuma,
T., Tanaka, M., Amano, N., Watanabe, A., Sakurai, H., et al. (2015).
Precise correction of the dystrophin gene in duchenne muscular
dystrophy patient induced pluripotent stem cells by TALEN and
CRISPR-Cas9. Stem Cell Rep. 4, 143–154.
Ohno, T., Akase, T., Kono, S., Kurasawa, H., Takashima, T., Kaneko,
S., and Aizawa, Y. (2022). Biallelic and gene-wide genomic substitution for endogenous intron and retroelement mutagenesis in human cells. Nat. Commun. 13, 4219.
Loeff, L., Brouns, S.J.J., and Joo, C. (2018). Repetitive DNA Reeling
by the Cascade-Cas3 Complex in Nucleotide Unwinding Steps.
Mol. Cell 70, 385–394.e3.
Long, C., Amoasii, L., Mireault, A.A., McAnally, J.R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J.M., Bassel-Duby, R.,
and Olson, E.N. (2016). Postnatal genome editing partially restores
dystrophin expression in a mouse model of muscular dystrophy.
Science 351, 400–403.
Martins-Taylor, K., Nisler, B.S., Taapken, S.M., Compton, T., Crandall, L., Montgomery, K.D., Lalande, M., and Xu, R.H. (2011).
Recurrent copy number variations in human induced pluripotent
stem cells. Nat. Biotechnol. 29, 488–491.
Mashiko, D., Fujihara, Y., Satouh, Y., Miyata, H., Isotani, A., and
Ikawa, M. (2013). Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA.
Sci. Rep. 3, 3355.
Mercuri, E., Bo¨nnemann, C.G., and Muntoni, F. (2019). Muscular
dystrophies. Lancet 394, 2025–2038.
Min, Y.L., Li, H., Rodriguez-Caycedo, C., Mireault, A.A., Huang, J.,
Shelton, J.M., McAnally, J.R., Amoasii, L., Mammen, P.P.A., BasselDuby, R., and Olson, E.N. (2019). CRISPR-Cas9 corrects Duchenne
muscular dystrophy exon 44 deletion mutations in mice and human cells. Sci. Adv. 5, eaav4324.
Morisaka, H., Yoshimi, K., Okuzaki, Y., Gee, P., Kunihiro, Y., Sonpho, E., Xu, H., Sasakawa, N., Naito, Y., Nakada, S., et al. (2019).
CRISPR-Cas3 induces broad and unidirectional genome editing
in human cells. Nat. Commun. 10, 5302.
Ousterout, D.G., Kabadi, A.M., Thakore, P.I., Majoros, W.H., Reddy,
T.E., and Gersbach, C.A. (2015). Multiplex CRISPR/Cas9-based
genome editing for correction of dystrophin mutations that cause
Duchenne muscular dystrophy. Nat. Commun. 6, 6244.
Roshmi, R.R., and Yokota, T. (2021). Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A
Japanese Experience. Clin. Pharmacol. 13, 235–242.
Saifullah, Motohashi, N., Tsukahara, T., and Aoki, Y. (2022). Development of Therapeutic RNA Manipulation for Muscular Dystrophy. Front. Genome Ed. 4, 863651.
Tabebordbar, M., Zhu, K., Cheng, J.K.W., Chew, W.L., Widrick, J.J.,
Yan, W.X., Maesner, C., Wu, E.Y., Xiao, R., Ran, F.A., et al. (2016).
In vivo gene editing in dystrophic mouse muscle and muscle
stem cells. Science 351, 407–411.
Xu, L., Lau, Y.S., Gao, Y., Li, H., and Han, R. (2019). Life-Long AAVMediated CRISPR Genome Editing in Dystrophic Heart Improves
Cardiomyopathy without Causing Serious Lesions in mdx Mice.
Mol. Ther. 27, 1407–1414.
Yoshimi, K., Kunihiro, Y., Kaneko, T., Nagahora, H., Voigt, B., and
Mashimo, T. (2016). ssODN-mediated knock-in with CRISPR-Cas
for large genomic regions in zygotes. Nat. Commun. 7, 10431.
Young, C.S., Hicks, M.R., Ermolova, N.V., Nakano, H., Jan, M., Younesi, S., Karumbayaram, S., Kumagai-Cresse, C., Wang, D., Zack,
J.A., et al. (2016). A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function
in hiPSC-Derived Muscle Cells. Cell Stem Cell 18, 533–540.
Muntoni, F., Torelli, S., and Ferlini, A. (2003). Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet
Neurol. 2, 731–740.
Zhang, Y., Li, H., Min, Y.L., Sanchez-Ortiz, E., Huang, J., Mireault,
A.A., Shelton, J.M., Kim, J., Mammen, P.P.A., Bassel-Duby, R., and
Olson, E.N. (2020). Enhanced CRISPR-Cas9 correction of
Duchenne muscular dystrophy in mice by a self-complementary
AAV delivery system. Sci. Adv. 6, eaay6812.
Nakamura, A., Yoshida, K., Fukushima, K., Ueda, H., Urasawa, N.,
Koyama, J., Yazaki, Y., Yazaki, M., Sakai, T., Haruta, S., et al.
(2008). Follow-up of three patients with a large in-frame deletion
of exons 45-55 in the Duchenne muscular dystrophy (DMD)
gene. J. Clin. Neurosci. 15, 757–763.
Zhao, M., Tazumi, A., Takayama, S., Takenaka-Ninagawa, N., Nalbandian, M., Nagai, M., Nakamura, Y., Nakasa, M., Watanabe, A.,
Ikeya, M., et al. (2020). Induced Fetal Human Muscle Stem Cells
with High Therapeutic Potential in a Mouse Muscular Dystrophy
Model. Stem Cell Rep. 15, 80–94.
Stem Cell Reports j Vol. 18 j 1753–1765 j September 12, 2023 1765
...
論文の公開元へ
